Minerva Neurosciences’ (NERV) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report released on Wednesday,Benzinga reports. The brokerage currently has a $5.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com started coverage on shares of Minerva Neurosciences in a research report on Saturday, February 22nd. They issued a “sell” rating for the company.

Minerva Neurosciences Stock Performance

Shares of NASDAQ NERV opened at $1.67 on Wednesday. Minerva Neurosciences has a 52-week low of $1.64 and a 52-week high of $3.69. The firm has a 50 day moving average price of $2.14 and a two-hundred day moving average price of $2.38. The stock has a market cap of $11.68 million, a P/E ratio of -3.80 and a beta of 0.12.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.49. Analysts predict that Minerva Neurosciences will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Citadel Advisors LLC boosted its stake in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,764 shares of the biopharmaceutical company’s stock after purchasing an additional 8,525 shares during the quarter. Citadel Advisors LLC owned about 0.37% of Minerva Neurosciences worth $57,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.